Gene editing has had a big week in the spotlight. Here’s what’s going on
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Category: drug pricing
STAT+: Medicare is urged to consider Amgen patent maneuvers when negotiating the price for a drug
As Medicare prepares to negotiate prices for its first batch of medicines, an advocacy group…
Sarepta’s disappointing data put the FDA in a difficult spot
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Senate committee plans Nov. 8 vote on wide-ranging health care package
WASHINGTON — The Senate Finance Committee plans to vote Nov. 8 on legislation that includes…
.jpg)
The XBI biotech index hit its lowest point since 2018. No one knows what comes next.
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Wegovy doesn’t work for everyone, and no one’s quite sure why
Want to stay on top of the science and politics driving biotech today? Sign up to get…
With Ozempic, Wall Street moves on from a whole other class of medicines
Want to stay on top of the science and politics driving biotech today? Sign up to get…
NIH funds expanded access projects for ALS
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Moderna’s plan to make a single vaccine for Covid, influenza, and RSV is on track
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Gene therapy makers wonder if they can make a profit in Europe. Patients fear being left behind — again
LONDON — It was when she was 12 that doctors first raised the prospect of…
STAT+: Court allows Medicare drug price negotiation to proceed
WASHINGTON — A federal court judge allowed a new Medicare drug price negotiation program to…
STAT+: Unitaid slams J&J over pricing and patents for a tuberculosis drug
In a highly unusual move, Unitaid has publicly criticized Johnson & Johnson over its pricing…
STAT+: Just how much money do drugmakers gain from patent extensions?
Extending patent protection doesn’t just stretch a drug’s profits — in some cases, doing so…
STAT+: AstraZeneca CEO Pascal Soriot proposes a novel fix to the drug pricing bill’s alleged cancer problem
Among the pharmaceutical companies’ many objections to the Biden administration’s drug pricing program is a…
STAT+: J&J cuts the price of its life-saving TB pill by more than half for many low and middle-income countries
Amid controversy over access to a life-saving tuberculosis pill, a new contracting effort is expected…
STAT+: Pharmalittle: Regeneron wins a delayed approval; Bristol, J&J likely to face pricing negotiation
Good morning, everyone. Damian Garde here, filling in for Ed Silverman on yet another dog…
STAT+: ViiV Healthcare and Doctors Without Borders tussle over contract terms for an HIV drug
A feud has erupted between ViiV Healthcare and Doctors Without Borders over a deal to…
STAT+: Blue Shield of California overhauls drug pricing operation — by adding more vendors
Blue Shield of California, a health insurance company that covers almost 5 million people, is…
STAT+: U.S. appeals court strike down key provisions in Oklahoma law that regulates PBMs
A U.S. appeals court struck down key parts of an Oklahoma law designed to regulate…
STAT+: From drug shortages to high prices, U.S. system’s shortcomings have deep roots
American medicine is a tragic paradox. An example: Cancer patients are likely dying as a…
STAT+: Genentech weighs slow-walking ovarian cancer therapy to make more money under drug pricing reform
WASHINGTON — Plenty of pharmaceutical executives have decried Democrats’ new drug pricing law as detrimental…
STAT+: More drugmakers are filing continuation patents that sideline generic competition
Amid concerns that the pharmaceutical industry unfairly wins monopolies on medicines, a new analysis finds…
STAT+: Nektar Therapeutics sues Lilly for ‘misconduct’ in drug development deal
A behind-the-scenes feud over a drug development program erupted into public view as Nektar Therapeutics…
STAT+: Vertex faces renewed calls to widen access to its cystic fibrosis medicines in poor countries
Several Latino advocacy groups and more than 100 clinicians from dozens of countries are lending…
.jpg)
STAT+: Senate panel advances PBM reform — but sidesteps anything controversial
WASHINGTON — Senators on the Finance Committee on Wednesday nearly unanimously passed a bill to…
STAT+: Democrats already want to expand Medicare’s drug price negotiation
WASHINGTON — It’s drug pricing déjà vu: Just as they did in 2019, House Democrats…
STAT+: Congress’s PBM reforms won’t end America’s drug pricing woes. Here’s what they would do
WASHINGTON — Lawmakers in Congress generally agree that there’s something very broken with the way America…
STAT+: South Africa faces court hearing over opaque Covid-19 vaccine contracts
A hearing began in a South Africa court on Tuesday to determine whether the government…
STAT+: Pharmalittle: Biogen to slash 1,000 more jobs; key House panel proposes lowering Medicare out-of-pocket drug costs
Rise and shine, everyone, another busy day is on the way. This morning is getting…
STAT+: Key House panel proposes lowering out-of-pocket drug costs in Medicare
WASHINGTON — A key House committee announced their own plans to increase health care transparency…
Opinion: Drug pricing and the ‘impossible trinity’ for patients
You don’t have to be an economist to understand the law of demand: The higher…
STAT+: Bernie Sanders wants to replace drug patents with prizes for breakthrough medicines
WASHINGTON — Sen. Bernie Sanders (I-Vt.) will finally get a study of his proposal to…
STAT Virtual Event: The State of Biosimilars: What to Watch
Editor’s note: A livestream of the event will be embedded below at 1 p.m. ET. Now…
STAT+: Colombian government explores compulsory licensing for an HIV drug
The latest clash over the cost of a prescription medicine is playing out in Colombia,…
STAT+: How a key Senate committee is planning to regulate pharmacy benefit managers
WASHINGTON — A key Senate health care panel has developed a plan to tackle reforms…
Biden’s NIH nominee is languishing in Congress — alarming public health advocates
WASHINGTON — Sen. Bernie Sanders’ rare move to delay President Biden’s health care nominees has…
STAT+: Medicare wants to send $9 billion to 340B hospitals — coupled with cuts
WASHINGTON — Medicare is planning to send $9 billion in lump sum payments to more…
STAT+: From ‘Jeopardy!’ to Politico, the PBM ad wars are taking over D.C.
WASHINGTON – If you live in this city, you’re probably awash in pharmacy benefit manager…
Opinion: Sen. Bill Cassidy: Smart, practical ways to lower drug prices
In the 1952 Oscar-winning movie “High Noon,” Gary Cooper’s face was tense and pained as…
STAT+: Medicare details the structure of its new drug price negotiation program
WASHINGTON — Medicare on Friday released new details about how its new drug price negotiation…
We have a cure for hepatitis C — so why aren’t more people getting treatment?
In 2005, Nick Voyles was diagnosed with hepatitis C after being released from five years…
STAT+: Trump demands the U.S. pay no more for drugs than other countries … again
WASHINGTON — Former President Trump is back to campaigning for tying Medicare drug prices to…
STAT+: ‘It’s like Groundhog Day’: The cancer drug shortage isn’t new — and neither are the solutions
A young girl, maybe 5 or 6 years old, had come into Yoram Unguru’s clinic…
STAT+: U.K. agency declines to recommend Eli Lilly’s Mounjaro for type 2 diabetes
LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s…
STAT+: STAT-Harris Poll: Nearly half of U.S. adults would spend $100 a month for Ozempic, other weight-loss drugs
Almost half of Americans would be willing to spend up to $100 a month for…
STAT+: The strategy behind the pharmaceutical industry’s flurry of lawsuits challenging drug pricing reform
WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere….
STAT+: U.S. seeks a new trial over royalties on Gilead HIV prevention pills
The U.S. government asked a federal judge to overturn a recent case in which a…
STAT+: Drug middlemen catch flak at another congressional hearing
Drug middlemen once again were on the hot seat at a congressional hearing on Wednesday….
Sen. Grassley calls on GOP leaders to rally support for PBM reforms
WASHINGTON — Republican Sen. Chuck Grassley wants to see his party’s leadership turn up the…
STAT+: PhRMA sues Biden administration over Medicare drug price negotiation program
WASHINGTON — After losing the drug pricing fight on Capitol Hill, PhRMA is taking its battle…